Puma Biotechnology

Puma Biotechnology(PBYI)

LOS ANGELES, CA
Biotechnology
WebsiteLinkedInCareers Page

Focus: Acquisition & Development of cancer therapies

Puma Biotechnology is a life sciences company focused on Acquisition & Development of cancer therapies.

Oncology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (1)

NERLYNX
neratinib
Peak
SMORAL · TABLET
(EGFR), HER2, and HER4. In vitro , neratinib reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and showed antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines. Neratinib human metabolites M3, M6, M7 and M11 inhibited the activity of EGFR, HER2, and HER4 in vitro. In vivo , oral administration of neratinib inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR.
metastatic HER2-positive breast cancerbreast cancer
2017
0

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2010
Portfolio: 1 approved product
Top TAs: Oncology
SEC Filings: 2 available
Portfolio Health
Peak1 (100%)
1 total products
Therapeutic Area Focus
Oncology
1 marketed
Marketed
Pipeline

Financials (FY2025)

Revenue
$236M3%
R&D Spend
$50M(21%)4%
Net Income
$22M
Cash
$69M
Source: SEC 10-K Filing

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 3 crawl cycles